Program
DCY636
A development code.
Its studies are mostly in Dermatitis, Atopic, led by Novartis.
Furthest: phase 1, since May 18, 20261 company-led study, 1 open or runningNext primary completion: Jan 27, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 1since May 18, 2026 | May 18, 2026 | Jan 27, 2028phase 1 · NCT07604324 |
- Named in Novartis’s own pipeline as
DCY636
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2026First study: phase 1 study in Dermatitis, AtopicFirst studyNCT07604324 · 63 planned · Japan
Ahead
- Jan 27, 2028Primary completion: phase 1 study in Dermatitis, AtopicNCT07604324
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07604324Dermatitis, Atopic · Japan | 1 | Recruiting | Jan 27, 2028 | 63 |
How it is read
Names in the registry
- “DCY636”, 1 entry
Codes read as this program: DCY636.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.